Acura Pharmaceuticals, Inc.  

(Public, NASDAQ:ACUR)   Watch this stock  
Find more results for ACUR
+0.26 (9.29%)
Real-time:   1:17PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.49 - 3.07
52 week 2.05 - 6.75
Open 2.89
Vol / Avg. 45,525.00/18,273.00
Mkt cap 33.37M
P/E     -
Div/yield     -
EPS -0.14
Shares 59.01M
Beta 1.64
Inst. own 44%
Nov 2, 2015
Q3 2015 Acura Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Aug 4, 2015
Q2 2015 Acura Pharmaceuticals Inc Earnings Call
Aug 3, 2015
Q2 2015 Acura Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -780.94% -1758.86%
Operating margin -703.23% -1624.37%
EBITD margin - -1561.12%
Return on average assets -65.07% -59.15%
Return on average equity -199.54% -114.99%
Employees 15 -
CDP Score - -


Suite 120, 616 N. North Court
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed two proprietary technologies. The Company’s Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. The Company’s Impede Technology is a combination of inactive ingredients preventing the extraction of pseudoephedrine from tablets and disrupts the direct conversion of pseudoephedrine from tablets into methamphetamine. The Company has seven additional opioid products utilizing Aversion in various stages of development. The Company markets products using telemarketing, direct mail, and online and journal advertising.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 62
Bio & Compensation  - Reuters
Robert A. Seiser CPA Vice President, Corporate Controller and Treasurer
Age: 51
Bio & Compensation  - Reuters
J. Bradley Rivet Vice President - Marketing
Age: 61
Bio & Compensation  - Reuters
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 58
Bio & Compensation  - Reuters
James F. Emigh Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
George K. Ross Independent Director
Age: 73
Bio & Compensation  - Reuters
William G. Skelly Independent Director
Age: 64
Bio & Compensation  - Reuters
Immanuel Thangaraj Independent Director
Age: 44
Bio & Compensation  - Reuters
Bruce F. Wesson Independent Director
Age: 72
Bio & Compensation  - Reuters